Skip to main content
TipRanks
Go Ultimate75% OFF

Arrowhead Pharmaceuticals (0HI3) Share Price & Analysis

0 Followers

0HI3 Stock Chart & Stats

$42.83-$1.96(-4.38%)
At close: 4:30 PM GMT
$40$60$80Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$42.41 - $45.00
52-Week Range
$37.07 - $95.49
Previous Close
$44.79
Volume
N/A
Average Volume (3M)
1,555
Market Cap
$6.08B
Enterprise Value
$9.46B
Total Cash (Recent Filing)
$1.19B
Total Debt (Recent Filing)
$1.00B
Price to Earnings (P/E)
―
Beta
1.27
Next Earnings
Feb 10, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Early Commercial Adoption And Payer Access

REDEMPLO is showing measurable early adoption through rising prescriptions, a growing prescriber base, and broadening payer coverage. These commercial foundations can support more durable product revenue as physician familiarity, reimbursement processes, and patient access improve over the next several quarters.

Strong SHTG Clinical Efficacy And Regulatory Progress

Consistent success across pivotal studies strengthens the clinical and regulatory case for plozasiran in severe hypertriglyceridemia. The combination of substantial lipid reduction and priority-review progress could support a meaningful commercial opportunity if approval and labeling are achieved.

Improved Debt Structure And Financing Flexibility

Refinancing materially improves the terms and maturity profile of Arrowhead's debt compared with the retired facility. Lower financing costs, no near-term scheduled amortization, and removal of cash-sweep requirements provide greater flexibility to fund development and commercialization activities.

Bears Say

Large Losses And Renewed Cash Burn

The return to substantial operating and free-cash-flow deficits shows that current activities are consuming capital faster than the business generates it. Persistent losses and spending needs may increase reliance on financing, limit strategic flexibility, and pressure liquidity before products scale.

Sharp Increase In Leverage And Reduced Balance-sheet Flexibility

The sharp increase in leverage leaves Arrowhead with less financial resilience while its operating results remain loss-making. A large debt burden relative to equity can constrain capital allocation, increase refinancing or dilution risk, and make future setbacks more difficult to absorb.

Commercial Conversion And Launch Execution Risk

Prescription growth has not yet translated automatically into paid treatment, because reimbursement and administrative steps remain necessary for each patient. Continued conversion friction could delay revenue scaling, raise commercialization demands, and weaken the pace at which market access becomes recurring sales.

Arrowhead Pharmaceuticals News

0HI3 FAQ

What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest share price was $37.07 and its highest was $95.49 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $6.08B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s next earnings report is estimated for Feb 10, 2027 (not yet confirmed), which is in 83 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Nov 12, 2026. The company reported -$3.04 earnings per share for the quarter, missing the consensus estimate of -$1.518 by -$1.522.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -1.50.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 141,368,010 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$3.04 in its last earnings report, missing expectations of -$1.518. Following the earnings report the stock price went down -0.932%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Hedge funds hold Arrowhead Pharmaceuticals shares: the largest hedge-fund position in Arrowhead Pharmaceuticals is 1,994,135,770 shares, and hedge funds decreased their holdings by 285.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology